Publikationen 2019

Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
Acta Oncol 2019; 58(3): 306-312;
Stenman M, Staehler M, Szabados B, Sandström P, Laurell A, Lindskog M, Harmenberg U

Distress in patients with renal cell carcinoma: a curious gap in knowledge.
BJU Int 2019; 123(2): 208-209;
Bergerot CD, Battle D, Staehler MD, Pal SK

Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?
BJU Int 2019; 123(5): 744-746;
Herlemann A, Meng MV

Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT).
BMC Urol 2019; 19(1): 29;
Magistro G, Bregenhorn P, Krauß B, Nörenberg D, D'Anastasi M, Graser A, Weinhold P, Strittmatter F, Stief CG, Staehler M

Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?
Cancer Treat Rev 2019; 75(): 20-26;
Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, Briganti A, de Visschere P, Mathieu R, Valerio M, van den Bergh R, Ost P, Mirvald C, Tilki D, Ploussard G, Surcel C, EAU-YAU Prostate Cancer Working Party

A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy.
Cancers 2019; 12(1):
Shi R, Bao X, Weischenfeldt J, Schaefer C, Rogowski P, Schmidt-Hegemann NS, Unger K, Lauber K, Wang X, Buchner A, Stief C, Schlomm T, Belka C, Li M

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
Clin Cancer Res 2019; 25(4): 1165-1173;
George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha H, Patel A, Lechuga MJ, Ravaud A

Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort.
Clin Genitourin Cancer 2019;
Schulz GB, Grimm T, Buchner A, Jokisch F, Kretschmer A, Stief CG, Knüchel R, Kraywinkel K, Karl A

Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
Clin Genitourin Cancer 2019; 17(5): 373-379.e4;
Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.
Clin Genitourin Cancer 2019; 17(2): e345-e355;
Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Clin Genitourin Cancer 2019; 17(3): e689-e703;
Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Clin Genitourin Cancer 2019; 17(1): 1-6;
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM

Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting.
Clin Hemorheol Microcirc 2019; 71(2): 165-170;
Schlenker B, Apfelbeck M, Chaloupka M, Stief CG, Clevert DA

Evidence of gleason 6 prostate cancer in mpMRI-targeted biopsy does not contribute to risk assessment of low risk prostate cancer.
Clin Hemorheol Microcirc 2019;
Chaloupka M, Bischoff R, Pfitzinger P, Lellig E, Ledderose S, Buchner A, Schlenker B, Stief C, Clevert DA, Apfelbeck M

Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion.
Clin Hemorheol Microcirc 2019;
Apfelbeck M, Chaloupka M, Schlenker B, Stief CG, Clevert DA

Fournier´s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature.
Cureus 2019; 11(9):
Rodler S, Weig T, Finkenzeller C, Stief C, Staehler M

Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy.
Cureus 2019; 11(9);
Ziegelmueller BK, Spek A, Szabados B, Casuscelli J, Buchner A, Stief C, Staehler M

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.
Cureus 2019; 11(3):
Schlemmer M, Spek A, Rodler S, Schott M, Casuscelli J, Staehler M

Evolution: Decoy Receptors as Unique Weapons to Fight Pathogens.
Curr Biol 2019; 29(4): R128-R130;
Zimmermann W

Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
Curr Opin Urol 2019; 29(6): 605-611;
Overland MR, Washington SL, Carroll PR, Cooperberg MR, Herlemann A

A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast.
Eur Urol 2019; 75(4): 546-547;
Derweesh IH, Staehler M, Uzzo RG

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Eur Urol 2019; 75(5): 799-810;
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SF, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
Eur Urol 2019; 75(1): 176-183;
Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).
Eur Urol 2019; 75(2): 261-264;
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A

Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).
Eur Urol 2019; 75(4): 692-693;
Kretschmer A, Gleave ME

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Eur Urol 2019; 76(2): 151-156;;
Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernandéz-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A

Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
Eur Urol Focus 2019; 5(4): 642-649;
Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA

Clinical Trials in Benign Prostatic Hyperplasia: A Moving Target of Success.
Eur Urol Focus 2019; 5(6): 1101-1104;
Thomas D, Chung C, Zhang Y, Te A, Gratzke C, Woo H, Chughtai B

Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe.
Eur Urol Focus 2019; 5(2): 155-158;
Herlemann A, Washington SL, Cooperberg MR

Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
Eur Urol Focus 2019; 5(6): 1029-1057;
Campi R, Brookman-May SD, Subiela Henríquez JD, Akdo?an B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinós E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O

Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).
Eur Urol Focus 2019; 5(5): 756-787;
Brookman-May SD, Campi R, Henríquez JDS, Klatte T, Langenhuijsen JF, Brausi M, Linares-Espinós E, Volpe A, Marszalek M, Akdogan B, Roll C, Stief CG, Rodriguez-Faba O, Minervini A

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
Eur Urol Focus 2019; 5(5): 857-866;
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Eur Urol Focus 2019; 5(6): 1022-1028;
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C, Azzouzi AR

Midterm Health-related Quality of Life After Radical Cystectomy: A Propensity Score-matched Analysis.
Eur Urol Focus 2019;
Kretschmer A, Grimm T, Buchner A, Jokisch F, Ziegelmüller B, Casuscelli J, Schulz G, Stief CG, Karl A

Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print].
Eur Urol Focus 2019;
Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Eur Urol Focus 2019; 5(6): 958-969;
Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S

The Urinary Tract Microbiome: The Answer to All Our Open Questions?
Eur Urol Focus 2019; 5(1): 36-38;
Magistro G, Stief CG

Urological Infections: "The Time for Change is Now".
Eur Urol Focus 2019; 5(1): 1;
Magistro G

Vaccine Development for Urinary Tract Infections: Where Do We Stand?
Eur Urol Focus 2019; 5(1): 39-41;
Magistro G, Stief CG

Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.
Eur Urol Oncol 2019; 2(2): 141-149;
Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, van Poppel H, Bensalah K, Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology

Effect of combined sublethal X-ray irradiation and cyclosporine A treatment in NOD scid gamma (NSG) mice.
Exp Anim 2019; 68(1): 1-11;
Walcher L, Müller C, Hilger N, Kretschmer A, Stahl L, Wigge S, Rengelshausen J, Müller AM, Fricke S

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.
Front Oncol 2019; 9(): 11;
Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.
Hum Pathol 2019; 83(): 212-223;
Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A, German Network Of Kidney Cancer

In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections.
Infection 2019; 47(6): 937-944;
Marcon J, Schubert S, Stief CG, Magistro G

Adjuvant therapy in renal cell carcinoma: the perspective of urologists.
Int J Clin Oncol 2019; 24(6): 694-697;
Spek A, Szabados B, Casuscelli J, Stief C, Staehler M

Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
Int J Urol 2019; 26(5): 532-542;
Berquist SW, Yim K, Ryan ST, Patel SH, Eldefrawy A, Cotta BH, Bradshaw AW, Meagher MF, Bindayi A, McKay RR, Autorino R, Staehler M, Derweesh IH

Artificial Urinary Sphincter Cuff Size Predicts Outcome in Male Patients Treated for Stress Incontinence: Results of a Large Central European Multicenter Cohort Study.
Int Neurourol J 2019; 23(3): 219-225;
Queissert F, Huesch T, Kretschmer A, Anding R, Kurosch M, Kirschner-Hermanns R, Pottek T, Olianas R, Friedl A, Pfitzenmaier J, Naumann CM, Wotzka C, Nyarangi-Dix J, Hoffmann T, Herrmann E, Obaje A, Rose A, Homberg R, Abdunnur R, Loertzer H, Bauer RM, Haferkamp A, Schrader AJ

A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate.
J Biol Chem 2019; 294(32): 12231-12249;
Yu Q, Gratzke C, Wang R, Li B, Kuppermann P, Herlemann A, Tamalunas A, Wang Y, Rutz B, Ciotkowska A, Wang X, Strittmatter F, Waidelich R, Stief CG, Hennenberg M

Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro.
J Biophotonics 2019; 12(10);
Shi L, Buchner A, Pohla H, Pongratz T, Rühm A, Zimmermann W, Gederaas OA, Zhang L, Wang X, Stepp H, Sroka R

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses.
J Biophotonics 2019; 12(2): e201800149;
Shi L, Luo M, Zhang F, Zhang L, Wang B, Liu P, Zhang Y, Zhang H, Yang D, Zhang G, Zhou F, Stepp H, Sroka R, Chen WR, Wang X

Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis.
J Nucl Med 2019; 60(7): 963-970;
Schmidt-Hegemann NS, Chukwuka E, Minglun L, Rogowski P, Schaefer C, Stief C, Buchner A, Zamboglou C, Fendler WP, Ganswindt U, Cyran C, Bartenstein P, Belka C, Ilhan H

Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors.
J Surg Educ 2019; 76(2): 568-577;
Schulz GB, Grimm T, Buchner A, Jokisch F, Casuscelli J, Kretschmer A, Mumm JN, Ziegelmüller B, Stief CG, Karl A

Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
J Urol 2019; 201(6): 1097-1104;
Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Siva S

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet 2019; 393(10189): 2404-2415;
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, IMmotion151 Study Group

A matched-pair analysis of patients with medium-sized prostates (50 cc) treated for male LUTS with HoLEP or TURP.
Low Urin Tract Symptoms 2019;
Magistro G, Westhofen T, Stief CG, Weinhold P

[Benign prostatic enlargement: symptoms, diagnostics and therapy].
MMW Fortschr Med 2019; 161(8): 50-57;
Tamalunas A, Magistro G, Grimm T, Jokisch JF, Westhofen T, Schott M, Stief CG, Weinhold P

[Complicated urinary tract infection: not always uncomplicated].
MMW Fortschr Med 2019; 161(1): 44-47;
Bischoff R, Marcon J, Stief CG, Magistro G

Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. Score in patients undergoing surgery for renal masses.
Minerva Urol Nefrol 2019; 71(3): 249-257;
Sterzik A, Solyanik O, Eichelberg C, Jost M, Graser A, Lausenmeyer EM, Otto W, Waidelich R, Stief CG, Burger M, May M, Brookman-May SD

The STK16 inhibitor STK16-IN-1 inhibits non-adrenergic and non-neurogenic smooth muscle contractions in the human prostate and the human male detrusor.
Naunyn Schmiedebergs Arch Pharmacol 2019;
Li B, Wang X, Rutz B, Wang R, Tamalunas A, Strittmatter F, Waidelich R, Stief CG, Hennenberg M

Efficacy and safety of artificial urinary sphincter (AUS): Results of a large multi-institutional cohort of patients with mid-term follow-up.
Neurourol Urodyn 2019; 38(2): 710-718;
Tutolo M, Cornu JN, Bauer RM, Ahyai S, Bozzini G, Heesakkers J, Drake MJ, Tikkinen KAO, Launonen E, Larré S, Thiruchelvam N, Lee R, Li P, Favro M, Zaffuto E, Bachmann A, Martinez-Salamanca JI, Pichon T, De Nunzio C, Ammirati E, Haab F, Van Der Aa F

Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after 48 months: Results of a prospective and multicenter study.
Neurourol Urodyn 2019; 38(7): 1973-1978;
Grabbert M, Mumm JN, Klehr B, Kretschmer A, Gebhartl P, Gozzi C, Homberg R, May F, Rehder P, Stief CG, Bauer RM

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Neurourol Urodyn 2019; 38(2): 779-792;
Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

Ghrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues.
Oxid Med Cell Longev 2019;
Wang X, Wang Y, Gratzke C, Sterr C, Yu Q, Li B, Strittmatter F, Herlemann A, Tamalunas A, Rutz B, Ciotkowska A, Waidelich R, Liu C, Stief CG, Hennenberg M

Non-invasive measurement of erythrocyte zinc protoporphyrin in children.
Pediatr Res 2019; 85(3): 349-354;
Homann C, Hennig G, Maier F, Stepp H, Holdt LM, Vogeser M, Sroka R, Koletzko B

Fluorescence and Treatment Light Monitoring for Interstitial Photodynamic Therapy.
Photochem Photobiol 2019;
Heckl C, Aumiller M, Rühm A, Sroka R, Stepp H

Application of different noninvasive diagnostic techniques used in HMME-PDT in the treatment of port wine stains.
Photodiagnosis Photodyn Ther 2019; 25(): 369-375;
Wen L, Zhang Y, Zhang L, Liu X, Wang P, Shen S, Hu C, Guo L, Jiang W, Sroka R, Wang X

What is the most relevent factor causing pain during ALA-PDT? A multi-center, open clinical pain score research trial of actinic keratosis, acne and condylomata acuminata.
Photodiagnosis Photodyn Ther 2019; 26(): 73-78;
Zheng Z, Zhang LL, Shi L, Zhang YF, Bo W, Wu QQ, Fang F, Wang WQ, Sroka R, Wang XL

New strategies for inhibition of non-adrenergic prostate smooth muscle contraction by pharmacologic intervention.
Prostate 2019; 79(7): 746-756;
Yu Q, Gratzke C, Wang Y, Wang X, Li B, Strittmatter F, Herlemann A, Wang R, Tamalunas A, Waidelich R, Stief CG, Hennenberg M

Anesthesia for Open Radical Retropubic Prostatectomy: A Comparison between Combined Spinal Epidural Anesthesia and Combined General Epidural Anesthesia.
Prostate Cancer 2019;
Kofler O, Prueckner S, Weninger E, Tomasi R, Karl A, Niedermayer S, Jovanovic A, Müller HH, Stief C, Zwissler B, von Dossow V

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Prostate Cancer Prostatic Dis 2019; 22(1): 101-109;
Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA

Factors associated with the decline of psychological support in hospitalized patients with cancer.
Psychooncology 2019; 28(10): 2049-2059;
Pichler T, Dinkel A, Marten-Mittag B, Hermelink K, Telzerow E, Ackermann U, Belka C, Combs S, Gratzke C, Gschwend J, Harbeck N, Heinemann V, Herkommer K, Kiechle M, Mahner S, Pigorsch S, Rauch J, Stief C, Beckmann J, Heußner P, Herschbach P

Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.).
Scand J Urol 2019; 53(1): 14-20;
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A

Robotic-assisted Excision of Giant Prostatic Utricular Cysts: Technique, Outcomes and Follow-up.
Surg Technol Int 2019; 35(): 43-47;
Khoder WY, Gratzke C, Kretschmer A, Becker A, Stief C

Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction.
Urol Int 2019; 103(3): 350-356;
Schulz GB, Grimm T, Buchner A, Kretschmer A, Stief CG, Karl A, Jokisch F

Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study.
Urol Int 2019; (): 1-7;
Ziegelmueller BK, Jokisch JF, Buchner A, Grimm T, Kretschmer A, Schulz GB, Stief C, Karl A

Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome.
Urol Int 2019; (): 1-6;
Jokisch JF, Grimm T, Buchner A, Kretschmer A, Weinhold P, Stief CG, Karl A, Schulz GB

Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
Urol Oncol 2019; 37(8): 530.e9-530.e18;
Schulz GB, Grimm T, Sers C, Riemer P, Elmasry M, Kirchner T, Stief CG, Karl A, Horst D

[Active surveillance of prostate cancer : An update].
Urologe A 2019; 58(3): 329-340;
Chaloupka M, Westhofen T, Kretschmer A, Grimm T, Stief C, Apfelbeck M

[Aftercare of non-muscle invasive bladder cancer].
Urologe A 2019; 58(8): 943-952;
Schulz GB, Schlenker B, Stief CG

[Current controversies in the treatment of localized prostate cancer].
Urologe A 2019; 58(5): 524-528;
Bischoff R, Chaloupka M, Westhofen T, Grimm T, Schlenker B, Weinhold P, Tilki D, Stief CG, Kretschmer A

[Differentiated surgical treatment of male stress urinary incontinence-between intention and reality?]
Urologe A 2019; 58(6): 640-650;
Mühlstädt S, Hüsch T, Bauer RM

[Follow-up of renal cell carcinoma in a nonmetastatic stage].
Urologe A 2019; 58(1): 65-76;
Szabados B, Foller S, Schulz GB, Staehler M, Grimm MO, Stief CG, Casuscelli J

[Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment].
Urologe A 2019; 58(9): 1093-1106;
Schulz GB, Stief CG, Schlenker B

[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer].
Urologe A 2019; 58(5): 529-534;
Kretschmer A, Tilki D

[Management of localized prostate cancer].
Urologe A 2019; 58(5);
Hadaschik B, Stief CG

[Management of ureteral injuries].
Urologe A 2019; 58(2): 197-206;
Ledderose S, Beck V, Chaloupka M, Kretschmer A, Strittmatter F, Tritschler S

[Novel minimally invasive treatment options for male lower urinary tract symptom].
Urologe A 2019; 58(3): 254-262;
Magistro G, Stief CG, Gratzke C

[Prospective analysis of postoperative outcomes and complications of artificial urinary sphincter (AMS 800) implantation after previous buccal mucosa graft urethroplasty].
Urologe A 2019; 58(8): 929-930;
Grabbert M, Bauer RM

[Value of imaging in upper urinary tract tumors].
Urologe A 2019; 58(1): 5-13;
Schulz GB, Gresser EK, Casuscelli J, Strittmatter F, Tritschler S, Karl A, Stief CG, Nörenberg D

Comparative evaluation of tissue damage induced by ultrasound and impact dual-mode endoscopic lithotripsy versus conventional single-mode ultrasound lithotripsy.
World J Urol 2019;
Khoder W, Strittmatter F, Alghamdi A, Seitz M, Stief C, Bader MJ

Comparison of adjustable male slings and artificial urinary sphincter in the treatment of male urinary incontinence: a retrospective analysis of patient selection and postoperative continence status.
World J Urol 2019; 37(7): 1415-1420;
Grabbert M, Hüsch T, Kretschmer A, Kirschner-Hermanns R, Anding R, Rose A, Friedl A, Obaje A, Heidenreich A, Brehmer B, Naumann CM, Queissert F, Loertzer H, Pfitzenmaier J, Nyarangi-Dix J, Kurosch M, Olianas R, Homberg R, Abdunnur R, Schweiger J, Hofmann T, Wotzka C, Pottek T, Huebner W, Haferkamp A, Bauer RM

Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?
World J Urol 2019; 37(2): 277-287;
Marra G, Ploussard G, Futterer J, Valerio M, EAU-YAU Prostate Cancer Working Party

Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes.
World J Urol 2019; 37(11): 2385-2392;
Grimm T, Grimm J, Buchner A, Schulz G, Jokisch F, Stief CG, Karl A, Kretschmer A

Imaging modalities in synchronous oligometastatic prostate cancer.
World J Urol 2019; 37(12): 2573-2583;
Fütterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I, EAU-YAU Prostate Cancer Working Party

Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
World J Urol 2019; 37(7): 1353-1360;
Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, Miller F, Wetterauer U, Volkmer B, Gratzke C, Amend B

Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
World J Urol 2019; 37(2): 243-251;
Ploussard G, Borgmann H, Briganti A, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, EAU-YAU Prostate Cancer Working Group

The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade.
World J Urol 2019; 37(6): 1103-1109;
Beck V, Schlenker B, Herlemann A, Apfelbeck M, Buchner A, Gratzke C, Stief CG, Tritschler S